Biomedical and pharmaceutical stakeholders have heralded the news that Chinese researchers have successfully cloned a monkey and its potential to unlock further our understanding of complex diseases.
Sistemic is targeting the US by setting up an office in Boston, Mass, from which it will promote its services that use miRNA to identify and understand a compound’s activity in a simpler way than genomics or proteomics.
Dutch biotech Pharming has solidified its patent position in the
use of transgenic cattle to produce protein therapeutics through a
licence agreement with Advanced Cell Technology (ACT), a US company
developing stem cell therapies...
Australian politicians begin their first round of votes this week
to decide the fate of a controversial new law that could legalise
therapeutic embryonic cloning in the country for the first time.
The UK's Human Fertilisation and Embryology Authority (HFEA) has
called for a public consultation into the use of animal eggs to
create cloned hybrid or chimeric human embryos for laboratory-based
disease research.
Researchers at Newcastle's Centre for Life have been given the
go-ahead to create stem cells from unfertilised human eggs, thought
to be the first time that such a license has been granted in
Europe.
Scientists in the UK are tipped to be given approval this week to
create cloned human embryos to harvest stem cells to treat diabetes
patients and with the possibility of treating other diseases such
as Parkinson's and Alzheimer's.
A US partnership is hoping that rights to a new gene delivery
system will help it to develop avian transgenic technology as an
efficient and cost-effective biomanufacturing platform for the
production of human therapeutic protein...
Scientists in South Korea have isolated stem cells from a cloned
human embryo for the first time, bringing the use of cell- or
tissuse-based therapies for treating disease a step nearer. But the
work has also re-ignited the controversy...
French company genOway has become the first in the world to clone
rats, opening the way towards genetically-modified animals that can
be used as reliable, reproducible models of disease processes.
The axe looks set to fall on Scottish biotechnology company PPL
Therapeutics now that the company put itself up for sale, having
failed to convince investors of a rescue plan.
Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic
production.
Transgenic drug production company PPL Therapeutics has been rocked
by a decision by Germany's Bayer to walk away from their protein
development partnership, placing the future of the Scottish firm at
risk
